Nebulized Sub-dissociative Dose Ketamine for Treating Pain
CompletedPhase 4NCT03909607
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The investigators previous research study comparing the efficacy of intravenous ketamine to morphine showed ketamine to provide equivalent relief of moderate to severe acute pain in emergency department patients. A second study by the investigators showed that increasing the time of administration of the ketamine, from a push injection to a drip infusion, will minimize the adverse effects experienced by recipients of ketamine. The investigators now aim to see if nebulized subdissociative-dose ketamine administered as a single agent in a dose of 1.5 mg/kg via Breath-Actuated Nebulizers (BAN) over 5-15 minutes will provide a better pain relief in comparison to 1 mg/kg and 0.75 mg/kg doses or if the lower doses are equally as effective.
Study details
- Official title
- Comparison of Nebulized Sub-dissociative Dose Ketamine at Three Different Dosing Regimens for Treating Acute and Chronic Painful Conditions in the ED: A Prospective, Randomized Trial
- Conditions
- Interventions
- Drug: Ketamine 0.75 mg/kg
- Drug: Ketamine 1.0 mg/kg
- Drug: Ketamine 1.5 mg/kg
- Sponsor
- Antonios Likourezos
- Organization
- Maimonides Medical Center
- Start date
- 2019-04-16
- Primary completion
- 2020-10-30
- Sex
- All
- Age range
- from 18 Years to 120 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients age 18 and older * acute and chronic abdominal, flank, back, musculoskeletal pain, and traumatic pain as well as cancer pain * initial pain score of 5 or more on a standard 11- point (0 to 10) numeric rating scale. Exclusion Criteria: * altered mental status, * allergy to ketamine, * weight greater than 150 kg, * unstable vital signs (systolic blood pressure \<90 or\>180 mm Hg, * pulse rate \<50 or \>150 beats/min, * respiration rate \<10 or \>30 breaths/min) * alcohol or drug abuse * inability to provide consent * psychiatric illness (schizophrenia), * recent (4 hours before) opioid use.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03909607